Customer Publication

A role for androgen receptor variant 7 in sensitivity to therapy: Involvement of IGFBP-2 and FOXA1

Authors: K.M. Biernacka

Journal: Translational Oncology (2023)

Institution: University of Bristol Southmead Hospital

Research Areas: Cancer Research

Cell Lines: LNCaP, 22Rv1, VCaP (mycoplasma)

Summary: Prostate cancer (PCa) is one of the leading causes of cancer-related deaths in men. Localised PCa can be treated effectively, but most patients relapse/progress to more aggressive disease. One possible mechanism underlying this progression is alternative splicing of the androgen receptor, with AR variant 7(ARV7) considered to play a major role. In this paper, authors confirmed that ARV7-positive PCa cells were less sensitive to anti-cancer treatments. Also, with HoloMonitor ,they showed PCa cells with ARV7 exhibited an increased rate of cell division, proliferation, and motility, which could potentially contribute to a more aggressive phenotype. Furthermore, data suggest an interplay of FOXA1 and IGFBP-2 with ARV7-mediated acquisition of an aggressive prostate cancer phenotype.HoloMonitor M4 was used to study the proliferation, cell motility and cell division.

Keywords: HoloMonitor M4, cell proliferation, single cell tracking, cell motility, cell division, ARV7, androgen receptor, FOXA1, IGFBP-2, chemotherapy, prostate cancer

Read the article …